Arrowhead Research | ARWR - Net Income


Arrowhead Research reported $30.81M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Anika Therapeutics USD -4.87M 16.99M Mar/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Novartis USD 3.93B 96M Sep/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
TG Therapeutics USD 390.9M 362.71M Sep/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025
Xencor USD -6.03M 24.8M Sep/2025